Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 percent higher in participants who were aged 65 years or older. Previous trial ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in ...

But, if its pipeline of new products comes into play, including work on new treatments in oncology, then Moderna stock -- ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase 3 study.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which could set the stage for the company’s combination COVID-19 ...

The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor.

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced Monday.

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, it will simply be too late.

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults,” said Moderna’s chief executive officer, Stéphane Bancel. “The ...